Personal information

Verified email addresses

Verified email domains

breast cancer, aneuploidy, colorectal cancer, targeted therapy, cell cycle, microRNA, molecular biology
Australia

Activities

Employment (1)

Mater Research: Brisbane, AU

2024-03-01 to present | Senior Research Fellow (Cancer Program)
Employment
Source: Self-asserted source
Dr. Murugan Kalimutho

Education and qualifications (1)

Universita degli Studi di Roma Tor Vergata: Roma, Lazio, IT

2007-09-01 to 2010-09-30 | PhD in medical Biotechnology and Molecular Medicine (Department of Internal Medicine )
Education
Source: Self-asserted source
Dr. Murugan Kalimutho

Works (50 of 72)

Items per page:
Page 1 of 2

Identifying genetic vulnerabilities in cancers driven by defects in DNA-damage response

Breast
2029 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesis

bioRxiv
2021 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer

International journal of molecular sciences
2021 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Targeting BRF2 in Cancer Using Repurposed Drugs

Cancers
2021 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Targeting BRF2 in Cancer Using Repurposed Drugs

2021 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Targeting BRF2 in Cancer Using Repurposed Drugs

Cancers
2021-07-27 | Journal article
Contributors: Behnam Rashidieh; Maryam Molakarimi; Ammar Mohseni; Simon Manuel Tria; Hein Truong; Sriganesh Srihari; Rachael C. Adams; Mathew Jones; Pascal H. G. Duijf; Murugan Kalimutho et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer

International Journal of Molecular Sciences
2021-05-28 | Journal article
Contributors: Ashwini Makhale; Devathri Nanayakkara; Prahlad Raninga; Kum Kum Khanna; Murugan Kalimutho
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Cep55 overexpression promotes genomic instability and tumorigenesis in mice

Communications biology
2020 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Theranostics
2020 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer

International journal of cancer
2020 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Targeting BRF2 in Cancer with Repurposed Drugs Using in Silico Methods

2020-12-31 | Other
Contributors: Behnam Rashidieh; Maryam Molakarimi; Ammar Mohseni; Hein Truong; Sriganesh Srihari; Rachael C. Adams; Pascal H.G. Duijf; Murugan Kalimutho; Kum Kum Khanna
Source: check_circle
Crossref

Abstract LB-256: PDGFR$β$ blockade bypasses resistance to combined MEK1/2-JAK2 inhibition in triple-negative breast cancer via intratumoral CD8+ T-cells infiltration

2019 | Other
Source: Self-asserted source
Dr. Murugan Kalimutho

Author Correction: LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer

Scientific reports
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Blockade of PDGFR$β$ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer

Journal of Experimental & Clinical Cancer Research
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018)

SCIENTIFIC REPORTS
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Mechanisms of genomic instability in breast cancer

Trends in molecular medicine
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells

Oncogene
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Patterns of genomic instability in breast cancer

Trends in pharmacological sciences
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

PDGFIR beta blockade bypasses resistance to combined MEK1/2-JAK2 inhibition in triple-negative breast cancer via intratumoral CD8+ T-cells infiltration

CANCER RESEARCH
2019 | Conference paper
Source: Self-asserted source
Dr. Murugan Kalimutho

Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer

Annals of Oncology
2019 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

CEP 55 is a determinant of cell fate during perturbed mitosis in breast cancer

EMBO molecular medicine
2018 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling

The FASEB Journal
2018 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

GSK3$β$ inhibition confers survival advantage in Burkholderia pseudomallei-infected hyperglycaemic mice by regulating inflammatory response

Tropical Biomedicine (accepted)
2018 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer

Scientific reports
2018 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Po-212 CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo

ESMO Open
2018 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

CEP 55 is a determinant of cell fate during perturbed mitosis in breast cancer

EMBO Molecular Medicine
2018-09 | Journal article
Contributors: Murugan Kalimutho; Debottam Sinha; Jessie Jeffery; Katia Nones; Sriganesh Srihari; Winnie C Fernando; Pascal HG Duijf; Claire Vennin; Prahlad Raninga; Devathri Nanayakkara et al.
Source: check_circle
Crossref

Abstract PR04: Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasia

2017 | Other
Source: Self-asserted source
Dr. Murugan Kalimutho

Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression

2017 | Other
Source: Self-asserted source
Dr. Murugan Kalimutho

Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD 51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae

Molecular oncology
2017 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transition

Oncogene
2017 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer

Annals of Oncology
2017 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer

Annals of Oncology
2017 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells

Scientific reports
2017 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Adenosine 2B receptor expression on cancer cells promotes metastasis

Cancer research
2016 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis

Oncogene
2016 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer

Oncotarget
2016 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis

Oncotarget
2016 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis

Oncotarget
2016 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach

Molecular BioSystems
2016 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

CEP55 is a determinant of genomic instability in aneuploid breast cancer cells and facilitates anti-mitotic drugs resistance by interacting directly with HSF1

2015 | Other
Source: Self-asserted source
Dr. Murugan Kalimutho

Effects of the porcupine inhibitor, LGK974, on RNF43 mutant and wild type colorectal cancer cell lines

Journal of Gastroenterology and Hepatology
2015 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Targeted therapies for triple-negative breast cancer: combating a stubborn disease

Trends in pharmacological sciences
2015 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Abstract LB-116: Cep55, a master regulator of cytokinesis in breast cancer pathogenesis

2014 | Other
Source: Self-asserted source
Dr. Murugan Kalimutho

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer

Cell reports
2014 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer

Clinical Cancer Research
2014 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma

Clinical Cancer Research
2014 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer

Oncogenesis
2014 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma

Cancer research
2014 | Journal article
Source: Self-asserted source
Dr. Murugan Kalimutho

The c-MET-JAK1/2-STAT3 signalling axis is regulated by ADAM17 and is a key mediator of resistance to MEK inhibition in KRAS mutant colorectal cancer

The c-MET-JAK1/2-STAT3 signalling axis is regulated by ADAM17 and is a key mediator of resistance to MEK inhibition in KRAS mutant colorectal cancer
2013 | Book chapter
Source: Self-asserted source
Dr. Murugan Kalimutho

Axl Expression is a Poor Prognostic Marker and Regulates Tumour Cell Invasion and Migration in Colorectal Cancer

Axl Expression is a Poor Prognostic Marker and Regulates Tumour Cell Invasion and Migration in Colorectal Cancer
2012 | Book chapter
Source: Self-asserted source
Dr. Murugan Kalimutho
Items per page:
Page 1 of 2

Peer review (5 reviews for 4 publications/grants)

Review activity for Advanced science. (1)
Review activity for Biomedicine & pharmacotherapy. (2)
Review activity for Journal of experimental & clinical cancer research. (1)
Review activity for npj precision oncology. (1)